Publications by authors named "Ghassan S Kiwan"
Objective: The cardiovascular benefits of low-dose colchicine have been demonstrated in patients with coronary disease. Its effects were evaluated in this prespecified analysis in patients with type 2 diabetes (T2D) from the Colchicine Cardiovascular Outcomes Trial (COLCOT).
Research Design And Methods: COLCOT was a randomized, double-blinded trial of colchicine, 0.
Background: The randomized, placebo-controlled COLCOT (Colchicine Cardiovascular Outcomes Trial) has shown the benefits of colchicine 0.5 mg daily to lower the rate of ischemic cardiovascular events in patients with a recent myocardial infarction. Here, we conducted a post hoc pharmacogenomic study of COLCOT with the aim to identify genetic predictors of the efficacy and safety of treatment with colchicine.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers analyzed over 4,600 patients, dividing them based on how quickly they received colchicine after their MI; those treated within 3 days had the best outcomes regarding heart-related events compared to those treated later.
- * The findings suggest that initiating colchicine treatment early—ideally in the hospital—offers important benefits in reducing severe complications such as cardiac death, recurrent MI, and the need for urgent procedures.
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
Eur Heart J Qual Care Clin Outcomes
September 2021
Aims: In the randomized, placebo-controlled Colchicine Cardiovascular Outcomes Trial (COLCOT) of 4745 patients enrolled within 30 days after myocardial infarction (MI), low-dose colchicine (0.5 mg once daily) reduced the incidence of the primary composite endpoint of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina leading to coronary revascularization. To assess the in-trial period and lifetime cost-effectiveness of low-dose colchicine therapy compared to placebo in post-MI patients on standard-of-care therapy.
View Article and Find Full Text PDFBackground: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis.
Methods: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction.